Rosalind Advisors, Inc. — 13F Holdings & Portfolio
CIK 1622627 · latest 13F-HR filed 2026-05-14
Rosalind Advisors, Inc. manages $248.9M in 13F-reported U.S. long-equity assets across 38 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are DCTH (12.31%), XERS (7.53%), FENC (7.19%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 11 new positions, exited 8, added to 5, and trimmed 16.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$248.9M
Long-equity book
38
Distinct positions
2026-03-31
Filed 2026-05-14
+11 / −8 / ↑5 / ↓16
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- X4 PHARMACEUTICALS INC$2.9M +27.4%
- XERIS BIOPHARMA HOLDINGS INC$2.2M +13.1%
- EYEPOINT PHARMACEUTICALS INC$757.2K +6.0%
- NEURAXIS INC$654.7K +63.0%
- BIOFRONTERA INC$291.4K +44.8%
Top Trims
- VIRIDIAN THERAPEUTICS INC-$9.1M -65.0%
- CYBIN INC-$6.2M -45.8%
- CG ONCOLOGY INC-$5.7M -45.7%
- PROFOUND MEDICAL CORP-$3.0M -36.2%
- SAVARA INC-$3.0M -14.8%
New Positions
- VAXCYTE INC$16.9M
- VOR BIOPHARMA INC$12.5M
- CELLDEX THERAPEUTICS INC$10.5M
- BIOCRYST PHARMACEUTICALS INC$8.8M
- ATEA PHARMACEUTICALS INC$6.3M
Exited Positions
- REPLIMUNE GROUP INC$13.7M
- ASTRIA THERAPEUTICS INC$13.6M
- CYTOKINETICS INC$12.4M
- MIND MEDICINE MINDMED INC$10.0M
- Ocular Therapeutix, Inc$4.9M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | DELCATH SYSTEMS, INC. | DCTH | 24661P807 | $30.6M | 12.31% | 3,300,389 | SH |
| 2 | XERIS BIOPHARMA HOLDINGS INC | XERS | 98422E103 | $18.7M | 7.53% | 3,231,700 | SH |
| 3 | FENNEC PHARMACEUTICALS INC | FENC | 31447P100 | $17.9M | 7.19% | 2,908,201 | SH |
| 4 | SAVARA INC | SVRA | 805111101 | $17.5M | 7.03% | 3,203,721 | SH |
| 5 | VAXCYTE INC | PCVX | 92243G108 | $16.9M | 6.77% | 290,000 | SH |
| 6 | EYEPOINT PHARMACEUTICALS INC | EYPT | 30233G209 | $13.4M | 5.37% | 1,036,737 | SH |
| 7 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $13.3M | 5.33% | 3,214,766 | SH |
| 8 | VOR BIOPHARMA INC | VOR | 929033207 | $12.5M | 5.02% | 700,000 | SH |
| 9 | MEDIWOUND LTD | MDWD | M68830112 | $12.1M | 4.85% | 749,054 | SH |
| 10 | VERASTEM INC | VSTM | 92337C203 | $11.3M | 4.55% | 2,138,475 | SH |
| 11 | CELLDEX THERAPEUTICS INC | CLDX | 15117B202 | $10.5M | 4.21% | 330,000 | SH |
| 12 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $8.8M | 3.53% | 923,057 | SH |
| 13 | CYBIN INC | HELP | 23256X407 | $7.4M | 2.95% | 1,531,814 | SH |
| 14 | CG ONCOLOGY INC | CGON | 156944100 | $6.8M | 2.72% | 100,000 | SH |
| 15 | INSPIREMD INC | NSPR | 45779A846 | $6.4M | 2.56% | 3,905,743 | SH |
| 16 | ATEA PHARMACEUTICALS INC | AVIR | 04683R106 | $6.3M | 2.53% | 1,171,855 | SH |
| 17 | PROFOUND MEDICAL CORP | PROF | 74319B502 | $5.4M | 2.16% | 828,118 | SH |
| 18 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $4.9M | 1.97% | 250,401 | SH |
| 19 | REPLIMUNE GROUP INC Call | REPL | 76029N906 | $2.7M | 1.10% | 1,275,600 | SH |
| 20 | POLYPID LTD | PYPD | M8001Q126 | $2.6M | 1.05% | 597,926 | SH |
| 21 | MYOMO INC | MYO | 62857J201 | $2.6M | 1.04% | 3,847,272 | SH |
| 22 | TALPHERA INC | TLPH | 00444T209 | $2.5M | 1.01% | 3,353,916 | SH |
| 23 | OVID THERAPEUTICS INC | OVID | 690469101 | $2.5M | 0.99% | 1,107,994 | SH |
| 24 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $2.4M | 0.95% | 125,000 | SH |
| 25 | ONKURE THERAPEUTICS INC | OKUR | 68277Q105 | $1.8M | 0.74% | 443,763 | SH |
| 26 | LIPOCINE INC | LPCN | 53630X203 | $1.8M | 0.71% | 221,616 | SH |
| 27 | NEURAXIS INC | NRXS | 64134X201 | $1.7M | 0.68% | 286,138 | SH |
| 28 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $1.1M | 0.45% | 75,000 | SH |
| 29 | ANNEXON INC | ANNX | 03589W102 | $1.1M | 0.45% | 200,000 | SH |
| 30 | INVESCO QQQ TR Put | QQQ | 46090E953 | $1.1M | 0.42% | 250,000 | SH |
| 31 | AQUESTIVE THERAPEUTICS INC | AQST | 03843E104 | $1.0M | 0.42% | 250,000 | SH |
| 32 | SPDR S&P 500 ETF TR Put | XCNY | 78462F953 | $958.5K | 0.39% | 125,000 | SH |
| 33 | BIOFRONTERA INC | BFRI | 09077D209 | $941.6K | 0.38% | 1,163,962 | SH |
| 34 | KURA ONCOLOGY INC | KURA | 50127T109 | $813.0K | 0.33% | 100,000 | SH |
| 35 | REGENTIS BIOMATERIALS LTD | RGNT | M8211G108 | $768.4K | 0.31% | 251,510 | SH |
| 36 | VIRIDIAN THERAPEUTICS INC Put | VRDN | 92790C954 | $52.7K | 0.02% | 263,600 | SH |
| 37 | ARRIVENT BIOPHARMA INC Call | AVBP | 04272N902 | $0 | 0.00% | 108,900 | SH |
| 38 | UNIQURE NV Call | — | N90064901 | $0 | 0.00% | 295,800 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $248.9M | 38 | 0001622627-26-000015 |
| 2025-12-31 | 2026-02-12 | $284.5M | 42 | 0001622627-26-000011 |
| 2025-09-30 | 2025-11-13 | $292.6M | 39 | 0001622627-25-000038 |